Tyme Technologies Inc. (TYME)

[mcsharkey]

From yesterday's 10Q. Description of the trial that seems to have some data released SOON. Corporate coverage. The 10Q has a glossary for the terms entered here:[/quote]

HoPES Phase II Trial in Sarcoma 
 In early 2020, the open-label Phase 2 investigator sponsored trial of SM-88 therapy in sarcoma, …. 
 (1)	The first is SM-88 with Methoxsalen*, Phenytoin**, and Sirolimus*** (MPS) as salvage treatment in patients with mixed rare sarcoma. 
 (2)	The other is SM-88 with MPS as maintenance treatment for patients with metastatic Ewing’s sarcoma that had not progressed on prior therapy.[/quote]  
 The primary objectives are to measure: 
 ………Objective Response Rate (ORR)  and 
 ……….Progression Free Survival (PFS).  
 Secondary objectives include: 
 ……..Duration Of Response (DOR)  
 ……..Overall Survival (OS) 
 ……..Clinical Benefit Rate (CBR) using RECIST (Response Evaluation Criteria In Solid Tumors)[/quote] 
 Plus incidence of treatment-emergent Adverse Events (AEs).  
 The Joseph Ahmed Foundation is sponsoring this trial and the trial is being conducted by PI Dr.Chawla at the Sarcoma Oncology Center in Santa Monica, CA. 
   
 We anticipate that the trial will complete enrollment by the end of the first half of calendar year 2022.